ID   BLUE-1
AC   CVCL_1967
SY   BLUE1; Blue1
DR   BioSample; SAMN03473493
DR   cancercelllines; CVCL_1967
DR   Cell_Model_Passport; SIDM01515
DR   DepMap; ACH-001450
DR   DSMZ; ACC-594
DR   DSMZCellDive; ACC-594
DR   Lonza; 1506
DR   Wikidata; Q54797435
RX   PubMed=16697040;
RX   PubMed=21412927;
RX   PubMed=24590883;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Virology: EBV-negative.
CC   Doubling time: ~36-48 hours (PubMed=16697040); ~50 hours (DSMZ=ACC-594).
CC   Sequence variation: Gene fusion; HGNC; 14078; BACH2 + HGNC; 992; BCL2L1; Name(s)=BACH2-BCL2L1 (PubMed=21412927; DepMap).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=16697040).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): DepMap; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 11,13
ST   D16S539: 12
ST   D18S51: 15,16
ST   D19S433: 13
ST   D21S11: 28,32.2
ST   D2S1338: 14,16
ST   D3S1358: 18
ST   D5S818: 9,10
ST   D7S820: 7,10
ST   D8S1179: 14,16
ST   FGA: 21,24
ST   Penta D: 9,11
ST   Penta E: 12,13
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 14,17
DI   NCIt; C2912; Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   29Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=16697040; DOI=10.1016/j.leukres.2006.03.026;
RA   Burmeister T., MacLeod R.A.F., Reinhardt R., Mansmann V.,
RA   Loddenkemper C., Marinets O., Drexler H.G., Thiel E., Blau I.W.;
RT   "A novel sporadic Burkitt lymphoma cell line (BLUE-1) with a unique
RT   t(6;20)(q15;q11.2) rearrangement.";
RL   Leuk. Res. 30:1417-1423(2006).
//
RX   PubMed=21412927; DOI=10.1002/gcc.20863;
RA   Turkmen S., Riehn M., Klopocki E., Molkentin M., Reinhardt R.,
RA   Burmeister T.;
RT   "A BACH2-BCL2L1 fusion gene resulting from a t(6;20)(q15;q11.2)
RT   chromosomal translocation in the lymphoma cell line BLUE-1.";
RL   Genes Chromosomes Cancer 50:389-396(2011).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//